Along with several other European countries, Spain has restricted vaccines produced by the Anglo-Swedish drug maker to people over 60 after regulators linked it to a rare form of brain blood clots, mostly in younger women.
“After decisions by various European public health authorities to suspend use of the AstraZeneca vaccine in under 60-year-olds, we are setting out to urgently find scientific evidence to support decision-making around possible alternatives,” Raquel Yotti, director of the Carlos III Health Institute, told a news conference.
The trial will draw on a sample of 600 people of all ages from across Spain, said Jesus Frias Iniesta, clinical research coordinator at Carlos III.
A British study on mixing vaccines was expanded last week to include shots made by Moderna (MRNA.O) and Novavax (NVAX.O), while France and Germany are considering giving an alternative to under 60s who received a first dose of AstraZeneca. read more
Separately, Spain’s El Mundo newspaper reported the health ministry was considering delaying second doses for under 80-year-olds to maximise the number of people who received at least one injection.
Patients would receive a second shot of vaccines produced by Pfizer (PFE.N) and Moderna (MRNA.O) eight weeks after the first, El Mundo said. The European Medicines Agency recommends a 28-day gap between Moderna shots and 21 days between Pfizer.
The proposal would signal a sharp departure from Spain’s current strategy, which favours giving vulnerable age groups a full course of two shots as quickly as possible.
The health ministry said it was studying various proposals without giving any details.
Asked about the report at a news conference, health official Fernando Simon said it was best not to start a media debate based on a draft proposal.
Despite delays to the deployment of the one-shot Johnson & Johnson (JNJ.N) vaccine and supply disruptions at AstraZeneca, Spain still expects to have half its 47 million population fully inoculated by late July. read more
By Monday, 7.2% of the population had received a full course, while almost 20% had received at least one dose.
Our Standards: The Thomson Reuters Trust Principles.